Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temtokibart in moderate-to-severe atopic dermatitis
NCT05923099Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Sep 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of temtokibart in atopic dermatitis (AD), sponsored by LEO Pharma. Started Sep 2023; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05923099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05923099.